H. Jack West, MD

Opinion

For NSCLC, neoadjuvant, adjuvant, or both?

Author:: H. Jack West, MD

Publish date: August 7, 2023

I think it’s a great place for shared decision-making because if a patient hears about that and decides they’re not interested, I’ll be fine with t...

Opinion

Did an unfair system help ADAURA win on overall survival?

Author:: H. Jack West, MD

Publish date: June 9, 2023

Although I strongly suspect that the overall survival difference would have been significant without the disparity in access to osimertinib in the ...

Opinion

When practice-changing results don’t change practice

Author:: H. Jack West, MD

Publish date: April 3, 2023

But among many of my colleagues who favor adjuvant over neoadjuvant therapy, it isn’t necessarily the fine points of the data that present the real...

Opinion

Local therapies show promise for metastatic lung cancer

Author:: H. Jack West, MD

Publish date: February 15, 2023

Local therapy for colorectal cancer with limited liver-only metastases is now established as a path to potentially excellent long-term su...

Article

Advances in Non–Small Cell Lung Cancer From SITC 2022

Author:: H. Jack West, MD

Publish date: December 1, 2022

The role of gene mutations in outcomes and treatment resistance, a novel LAG-3 inhibitor, and the case for neoadjuvant therapy are among the NSCLC ...

Opinion

Discontinuing immunotherapy: Is the infusion bag half empty or half full?

Author:: H. Jack West, MD

Publish date: November 23, 2022

Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.

Article

Highlights in Advanced Non–Small Cell Lung Cancer From ESMO 2022

Author:: H. Jack West, MD

Publish date: October 5, 2022

Highlights in NSCLC from ESMO 2022 include sotorasib in KRAS G12C mutated disease, 5-year data on pembrolizumab, and nove...

Article

Key Data on Early Non–Small Cell Lung Cancer From ESMO 2022

Author:: H. Jack West, MD

Publish date: October 5, 2022

Osimertinib dosing periods, the use of ctDNA to predict recurrence, and the role of air pollution in promoting lung cance...

Opinion

Is a progression-free survival benefit alone really worth $10,000 a month?

Author:: H. Jack West, MD

Publish date: March 4, 2022

We consider the physician-patient relationship to be autonomous, but we ignore the fact that both are deciding on treatments that are funded by peo...

Opinion

Five reasons why medical meetings will never be the same

Author:: H. Jack West, MD

Publish date: September 9, 2020

Dr. Jack West argues that we shouldn’t necessarily rush to return to the previous status quo of live, in-person m...